Select Bibliography

Filter by any of these (after searching):

Stark, A

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance)

Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol. - 2020

Abstract - Primary - Primary - Lymphoma - CALGB-51101

A prospective economic analysis of Canadian Cancer Trials Group CLC.2/Alliance A041202: A randomized phase III comparison of bendamustine-rituximab versus ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia

Cheung, Matthew C. , Mittmann, Nicole , Owen, Carolyn ... - ASH - Blood - 2020

Abstract - Secondary-not-in-original - Primary - Leukemia - A041202

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials

Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - - Blood - 2011

Abstract - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-10101 , CALGB-19901

Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712

Woyach, J. , Heerema, N. A. , Stark, A. , Peterson, B. L. ... - - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-9712